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Christoph Böttcher,§ Roland R. Netz,† and Rainer Haag‡
‡Institute of Chemistry and Biochemistry, †Institute of Theoretical Physics, and §Research Centre of Electron Microscopy and Core
Facility BioSupraMol, Institute of Chemistry and Biochemistry, Freie Universitaẗ Berlin, Berlin, Germany
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ABSTRACT: Competitive binding inhibitors based on multi-
valent nanoparticles have shown great potential for preventing
virus infections. However, general design principles of highly
eﬃcient inhibitors are lacking as the quantitative impact of
factors such as virus concentration, inhibitor size, steric
shielding, or multivalency eﬀects in the inhibition process is
not known. Based on two complementary experimental
inhibition assays we determined size-dependent steric
shielding and multivalency eﬀects. This allowed us to adapt
the Cheng−Prusoﬀ equation for its application to multivalent
systems. Our results show that the particle and volume
normalized IC50 value of an inhibitor at very low virus
concentration predominantly depends on its multivalent association constant, which itself exponentially increases with the
inhibitor/virus contact area and ligand density. Compared to multivalency eﬀects, the contribution of steric shielding to the IC50
values is only minor, and its impact is only noticeable if the multivalent dissociation constant is far below the virus concentration,
which means if all inhibitors are bound to the virus. The dependence of the predominant eﬀect, either steric shielding or
multivalency, on the virus concentration has signiﬁcant implications on the in vitro testing of competitive binding inhibitors and
determines optimal inhibitor diameters for the eﬃcient inhibition of viruses.
■ INTRODUCTION
The eﬃcient inhibition of viral infection is a major challenge for
science. One approach to ﬁght viral infection is to inhibit the
virus binding to cells by competitive binding to viral proteins.
Small monovalent molecules, however, have shown to be
widely ineﬃcient for this purpose. Therefore, multivalent
inhibitors of diﬀerent sizes and shapes, i.e., linear poly-
mers,1−3 dendrimers,4−9 liposomes,10,11 polymersomes,12 nano-
gels,13 and nanoparticles,14−19 have been reported for the
inhibition of a large variety of viruses, i.e., Inﬂuenza
virus,1,2,11,13,20,21 VSV,22 HIV,4,8,14,15 HSV,17−19 or Ebola
virus.7,9 Recently we have used functionalized gold nano-
particles of diﬀerent sizes for the inhibition of viral binding and
infection.20 The observed size-dependent eﬀects were system-
atically studied for a more detailed understanding of multi-
valency eﬀects but raised new questions as the inhibition
eﬃciency indeed followed the trend of the contact area, but its
magnitude turned out to be exceptionally larger than
expected.22 An explanation for this phenomenon as well as a
general conclusion on the best size and shape for competitive
binding inhibitors, however, is still lacking. The main problem
is the accurate proportionate quantiﬁcation of the size-
dependent steric shielding and multivalency eﬀects on the
competitive binding inhibition, which are respectively the
ability of inhibitors to block additional areas on the virus
besides the contact area and the ampliﬁcation of a binding
constant due to multiple binding events.2,10,13,22−26 Nano-
particles are especially suited for quantifying the eﬀects as their
size can be precisely varied, whereby their high symmetry
facilitates geometric considerations on steric shielding.
However, the virus/nanoparticle contact area (and thus the
number of multiple ligand−receptor interactions) as well as the
steric shielding simultaneously increase upon increasing the
inhibitor size (Figure 1a). To distinguish between the size-
dependent steric shielding and multivalency eﬀects, we present
here two complementary inhibition assays that are respectively
based on a weak and a strong binding ligand/receptor pair
(Figure 1b,c). In order to have a well-controlled and
characterized system, we also have employed nanoparticles to
represent viruses, which we termed “binders”.
The neat size-dependent steric shielding eﬀect was
determined by using an analog of the commonly employed
hemagglutination inhibition assay (Figure 1b).22 In this assay,
the binding of streptavidin functionalized, ﬂuorescent silica
nanoparticles of 192 nm (SA-NP, binders) to biotinylated
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magnetic particles of 10 μm (BT-MP, target surface) was
inhibited by diﬀerently sized biotinylated silica nanoparticles
(BT-NP, inhibitors). Due to the very low dissociation constant
of a single streptavidin−biotin bond of approximately 10−15
M,29 the multivalency eﬀect was negligible as the dissociation
constant was far below the concentration of the SA-NP. We
determined the IC50 values for 7 diﬀerently sized BT-NP
ranging from 18 nm up to 413 nm (d < D and d > D). The
changes in the inhibitor size exclusively inﬂuenced the steric
shielding and therefore allowed direct quantiﬁcation of this
eﬀect.
The complementary assay employed weak ligand/receptor
binding pairs and was based on the respective inhibition of L-
selectin (Sel) functionalized binders by dendritic polyglycer-
olsulfate (dPGS) derivatized scaﬀolds of 12 diﬀerent sizes
(Figure 1c). L-selectin is a cell adhesion molecule that is
multivalently presented on leukocytes and initiates their
recruitment from the blood ﬂow in inﬂammatory processes.30
The Kd
mono of this ligand/receptor pair is estimated to be in the
order of 500 nM.31 In this case, the inhibition was not only
dependent on the steric shielding eﬀect but also on the binding
aﬃnity of the inhibitor, i.e., on the inhibitor/binder contact
area. Previously, we studied the binding inhibition of L-selectin
functionalized 45 nm gold nanoparticles (AuNP-Sel, binder)
with sulfated dendritic polyglycerol (dPGS) inhibitors.28 The
large amount of meaningful inhibition data made this assay
perfectly suitable for the study of multivalency eﬀects. As the
size of the inhibitors (dPGS, 2−17 nm) did not exceed the size
of the binder (AuNP-Sel, 45 nm) in this previous study, we
extended our study by also measuring dPGS functionalized gold
nanoparticles (AuNP-dPGS, inhibitors) in the size range of
25−98 nm.
In the present paper we demonstrate that the evaluation of
the inhibition characteristics of these two assays allows a
relative quantiﬁcation of the steric shielding and multivalency
contributions to the inhibition. The quantitative evaluation of
the inhibition mechanism will (1) help one to better
understand the origin of the often observed high eﬃcacy of
larger-sized inhibitors, (2) give important implications for in
vitro testing of inhibitors, (3) permit a quantitative rating of
design parameters, i.e., according to inhibitor size, inhibitor to
virus contact area, and ligand density and type for the rational
design of eﬃcient inhibitors, and (4) permit prediction of the
optimal inhibitor diameters for eﬃcient treatment of viral
infections.
■ RESULTS
The binders and inhibitors for the BT/SA and dPGS/Sel assays
were characterized by DLS, TEM, and AAS measurements,
respectively (Supporting Information, SI). A monomodal size
distribution of low polydispersity in PBS could be conﬁrmed
for all particles. The inhibition curves obtained from the BT/SA
and the dPGS/Sel assay, respectively, are presented in Figure 2.
The inhibition was plotted against the total concentration
ratio of inhibitors ([I]) to binders ([B]). For the BT/SA assay
(Figure 2a) steep inhibition curves were observed with 0−
100% inhibition within a concentration range of 1 order of
magnitude for all inhibitor diameters. Furthermore, the
required concentration of BT-NPs (inhibitors) to induce
comparable binding signals decreased with larger inhibitors,
but the ratio of inhibitor to binder concentration at 50%
inhibition generally exceeded a value of 1, even for inhibitor
sizes larger than the binder size. Similar inhibition character-
istics could be observed for the dPGS/Sel assay (Figure 2b).
Again, the inhibitor to binder concentration ratio decreased as
the inhibitor sizes increased but never fell below the value of 1
at 50% inhibition. The inhibition slope of smaller-sized dPGS-
based inhibitors, however, was signiﬁcantly more gentle
compared to larger sized inhibitors and often required a several
order of magnitude increase in particle concentration to obtain
100% inhibition.
Figure 1. (a) Schematic illustration depicting the concept of virus-cell
binding inhibition by globular inhibitors of diﬀerent sizes. The virus/
inhibitor contact area as well as the number of inhibitors required for a
steric shielding of a virus depends on the inhibitor and virus sizes,
denoted by d and D, respectively. (b,c) Schematic of the employed
inhibition assays. (b) Fluorescence-based competitive binding
inhibition assay of streptavidin functionalized, ﬂuorescent silica
nanoparticles of diameter D = 192 nm (SA-NP, binders) and biotin
functionalized silica nanoparticles (BT-NP, inhibitors) with diameters
d between 18 and 413 nm. The read-out was based on the ﬂuorescence
signal in the supernatant after magnetic removal of the noninhibited
SA-NP with biotin functionalized magnetic particles of 10 μm (BT-
MP, target surface). (c) SPR-based competitive binding inhibition
assay.27 L-selectin functionalized gold nanoparticles of diameter D = 45
nm (binders) were inhibited with dPGS (d = 3−17 nm)28 and AuNP-
dPGS (d = 25−86 nm, inhibitors), respectively.
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We complemented the inhibition assays with a direct visual
method by using the cryogenic transmission electron
microscopy technique (cryo-TEM) for several binding
inhibitors (Figure 3).
For the visualization of the binding in the BT/SA assay, we
chose the 54 nm inhibitors with the 192 nm binders (Figure
3a). For the dPGS/Sel assay, we considered AuNP-dPGS
(inhibitor) of 98 nm in combination with the AuNP-Sel
(binder) of 45 nm (Figure 3b,c). It is obvious from the images
that the distances between binders and inhibitors were rather
large, which was due to the fact that strong electron scattering
of metal nanoparticles prevents the visualization of low-density
organic layers. A mean particle distance of 20.7 nm ±2.3 nm,
however, was in good agreement with the combined
contribution of AuNP-dPGS (4.5 ± 1.5 nm) and the AuNP-
Sel (14.9 ± 1.3 nm) organic layers (see Figure 3b and SI).
Furthermore, clustering events of inhibitors and binders are
detectable to some extent in Figure 3. The presence of
clustering was therefore dependent on the employed particle
ratio. Clustering was more pronounced at particle ratios at
which the surface of the AuNP-dPGS was not saturated with
AuNP-Sel (Figure 3b). When the binder was used in excess,
clustering of inhibitors by binders did not occur (Figure 3c).
■ DISCUSSION
The inhibition data presented in Figure 2 indicate that there is a
critical size limit for inhibitors, above which larger inhibitor size
does not result in lower concentrations for inhibition. In order
to better understand this phenomenon, we had to quantify the
measured IC50 values in terms of steric shielding and
multivalency eﬀects. For this purpose, we ﬁrst considered the
Cheng−Prusoﬀ equation which is commonly employed for
calculating IC50 values depending on the concentration of a
monovalent binder [B]:32
= +KIC 0.5[B]50 dmono (1)
In contrast to the monovalent case, our binders were
multivalent by nature, therefore the dissociation constant of the
monovalent inhibitor Kd
mono was substituted with the eﬀective
dissociation constant of the multivalent inhibitor Kd
multi.
Furthermore, we had to consider the number of inhibitors
required to sterically shield a binder. This number is denoted as
P. To draw the analogy to eq 1, we had to rescale the binder
concentration with P.
Figure 2. Relative binding signals depending on the inhibitor [I] to
binder [B] concentration ratio for the (a) BT/SA and (b) dPGS/Sel
assays. The binders in (a) were streptavidin functionalized, ﬂuorescent
silica nanoparticle (SA-NP) of 192 nm and in (b) AuNP-Sel of 45 nm
diameter, respectively. The colored curves show the inhibition of the
binders for individual inhibitor sizes. In (b), additional data are shown
for corresponding molecular weights and degrees of dPGS sulfation.28
Figure 3. (a) TEM micrograph of d = 54 nm BT-NPs (inhibitors)
incubated with D = 192 nm SA-NPs (binders) at a BT-NP/SA-NP
concentration ratio of 15. Contact area, steric shielding area, and
particle diameters are marked. (b) Cryo-TEM micrograph of d = 98
nm AuNP-dPGS (inhibitors) with D = 45 nm AuNP-Sel (16 nm gold
core) (binders) at an AuNP-Sel/AuNP-dPGS concentration ratio of
30. Clustering eﬀects are clearly visible. The corona thickness of
AuNP-dPGS and AuNP-Sel of 19.4 ± 2.8 nm is indicated as
determined experimentally (see SI). (c) Cryo-TEM micrograph of d =
98 nm AuNP-dPGS with D = 45 nm AuNP-Sel at an AuNP-Sel/
AuNP-dPGS concentration ratio of 120. Clustering of inhibitors by
binders rarely occurred.
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A detailed derivation of eq 2 is provided in the SI. From eq 2,
it is evident that the IC50 value splits up into a multivalency and
a steric shielding term. In order to predict the steric shielding
term, we started with theoretical considerations. First, it was
necessary to determine the number of inhibitors P required to
prevent the attachment of the binder to the target surface. Two
scenarios emerged. In the ﬁrst scenario, a minimum number of
inhibitors arrange on the binder in order to inhibit its
attachment to a planar surface (Figure 4a, Pmin). The number
of inhibitors (Pmin) to do so is based on the ratio of the
sterically shielded area (Figure 4b, area marked in red) to the
overall surface area of the binder.
In the second scenario, inhibitors randomly arrange on the
binder. The decoration is therefore more dense and irregular
compared to the ﬁrst case (Figure 4a, Pmax). For the calculation
of Pmax, the area was considered which a single inhibitor needs
to shield a binder surface in a projection view (Figure 4b, area
marked in blue). The ratio of the binder surface area and the
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Second, individual inhibitors can simultaneously bind to
several binders because of their multivalent nature. This
process, which we termed clustering, increases the eﬃciency
as individual inhibitors bind to multiple binders within a cluster.
The number of binders a single inhibitor can bind (M) is again
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M was calculated in an analogous manner described for Pmax
(eq 4). Combining P with M allows one to describe clustering
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From eq 2 it follows that the number of inhibitors required
to fully inhibit a binder P can be directly obtained from the
measured IC50 value, if the dissociation constant Kd
multi is very
low (Kd
multi ≪ 0.5P[B]). In this limit P reads:
= · ≪P K P2 IC
[B] (
if 0.5 [B])50 d
multi
(8)
In Figure 5 the experimentally obtained P value according to
eq 8 is compared to the theoretical values of Pmin and Pmax (eqs
3 and 4), respectively.
The experimental data from the BT/SA-based assay (Figure
5) are best described by the theoretical curve progression of
Pmax, which implies a random packing of the inhibitors on the
binder (Figure 4a). We assume that the high packing density of
BT-NP is caused by the absence of charges (= absence of
interparticle repulsion) which is conﬁrmed by a random
packing of BT-NP observed by TEM (Figure 3a). The fact that
P is larger than two even at very large d/D ratios of 1.5 and 2.2
(corresponding to 300 and 413 nm sized BT-NPs) is an
indication that clustering does not have a major quantitative
impact on the inhibition. As the inhibitors of the BT/SA assays
inhibit according to the theoretical model for steric shielding
with (P = Pmax), the complete binding of all inhibitors to the
binder was conﬁrmed.
A similar trend was observed with the experimental data of
the dPGS/Sel assay. P never fell below a value of 2, which again
supports the ﬁnding that the formed clusters are of minor
impact. The experimental data for d/D ratios of 0.3−2 from the
dPGS/Sel assay, however, follow a diﬀerent trend if compared
to the BT/SA assay. They are best described by the course of
Pmin, which indicates a much lower packing density of the
Figure 4. (a) Schematic illustration of possible arrangements for
inhibitors (green) and binders (blue) depending on minimum (Pmin)
or random (Pmax) arrangement of inhibitors on the binder. To
illustrate the size dependency, selected scenarios of inhibitors smaller
than binders (d < D) and vice versa (d > D) are presented. (b)
Schematic illustration of the area shielded by the inhibitor on the
binder. The red marking deﬁnes the area which cannot bind to a
planar surface anymore (used for the calculation of Pmin), while the
blue marking deﬁnes the area which cannot bind to a second inhibitor
(used for the calculation of Pmax).
Figure 5. Combination of the experimental and theoretical numbers of
inhibitors P required to inhibit the binding of a binder to a planar
surface. The data points depicting the experimental data are colored in
red for the dPGS/Sel assay and in blue for the BT/SA assay,
respectively, as determined by eq 8. The dashed and continuous lines
represent the predicted values based on the theoretical models for Pmax
and Pmin with (eqs 6 and 7) and without (eqs 3 and 4) clustering,
respectively. The dotted gray line marks the situation for an inhibitor/
binder ratio of two (P = 2).
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inhibitors on the binder surface (Figure 4a). We assume that
this diﬀerence is due to the highly charged nature of the AuNP-
dPGS which results in electrostatic repulsion of the nano-
particles, and hence causes a lower packing density.
Furthermore, the correspondence of P with Pmin required at
d/D ratios above 0.3 implies that all inhibitors are ratnd to the
AuNP-Sel. This strong binding was conﬁrmed by cryo-TEM,
which showed almost no unbound AuNP-Sel particles (Figure
3b). For all ratios below d/D = 0.3, the experimental data
exhibited a signiﬁcant deviation from Pmax as well as Pmin. We
assume that this phenomenon was due to an increase of Kd
multi
for smaller inhibitors. In order to clarify this we further
investigated the IC50 values (Figure 6).
For the BT/SA assay, the measured IC50 values were
equivalent to the course of 0.5Pmax[B] (Figure 6a), which
indicates that Kd
multi ≪ 0.5Pmax[B] (see eq 2). Hence, the
observed changes in the IC50 values for diﬀerently sized
inhibitors were only based on steric shielding eﬀects. This was
expected, as the Kd
monoof BT/SA is approximately 10−15 M,29
i.e., several orders of magnitude lower than the concentration of
SA-NPs (binders) in the assay with [B] = 1.13 pM.
For the dPGS/Sel-based assay, however, we observed a
diﬀerent trend (Figure 6b). For smaller dPGS (d/D < 0.3), the
measured IC50 values were much higher than 0.5Pmin[B]. Thus,
the multivalent dissociation constants can be directly obtained
in this regime from the IC50 values.
Before we discuss the size dependency of the dissociation
constants, we will brieﬂy present a motivation for a heuristic
equation for Kd
multi. Starting from the dissociation constant of a
monovalent ligand/receptor pair Kd
mono = V exp[−ΔG/kBT]
(with ΔG the binding free energy of a monovalent ligand/
receptor pair, kBT as the thermal energy, and V a measure for
the volume of the binding site) the multivalent dissociation
constant reads:

















with α the so-called cooperativity factor and N the number of
interacting ligand/receptor pairs.24 Furthermore, we assume
that N is proportional to the contact area (Ac) between binder
and inhibitor. According to the JKR model,33 which describes
the relationship between the contact area of two elastic,
adhesive spheres and the diameters of the spheres, d and D,
respectively, the contact area is given by
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with g the binding energy per unit area and K the eﬀective
elastic constant. In the limit of a very large number of
interaction ligand/receptor pairs (N ≫ 1) Kdmulti reads:



























Equation 11 describes the experimental data well with Kd
mono
= 94 nM and γ = 0.34 nm−4/3 (Figure 6b, inset). For example,
Woelke et al. showed that the sulfate-dependent dissociation
constant toward L-selectin is approximately 500 nM,31 thus the
experimentally determined monovalent dissociation constant is
reasonable (Figure 6b, inset). Furthermore, the exponential
dependence of Kd
multi on N is in good agreement with a previous
study by Hong et al.,34 which reported an exponential
relationship for the binding of nanoparticles of varied ligand
densities at a ﬁxed diameter to multivalent surfaces. In eq 11,
the ligand density is incorporated in γ, which we term
ampliﬁcation factor. Furthermore, the factor γ includes the
deformability of the inhibitor as well as cooperative eﬀects. The
deformability and ligand density of the inhibitors employed in
the presented assays can be assumed to be nearly constant.
Even though the magnitude of cooperative eﬀects cannot be
determined, the ability to exponentially ﬁt the Kd
multi using a
constant prefactor indicates that cooperative eﬀects are
constant over the entire range of inhibitor sizes.
Now, the various factors aﬀecting the IC50 values of globular
inhibitors can be put in order. IC50 values are most of all
dependent on the inhibitor/binder contact area and the ligand
density, as both correlate with N and therefore, have an
exponential inﬂuence on the Kd
multi value (eq 11), which itself
directly correlates with the IC50 value (eq 2). Due to the
relationship of contact area and inhibitor diameter d (eq 10),
IC50 values also decrease exponentially with the inhibitor size.
Nevertheless, the beneﬁt of the inhibitor potential by
multivalency is only measurable as long as Kd
multi ≫ 0.5P[B].
If Kd
multi ≪ 0.5P[B], all inhibitors bind completely to the
binders and a further increase of the contact area or ligand
density does not have any measurable eﬀect on the IC50 values.
A further increase of the inhibitor diameter therefore lowers the
IC50 value only because of the enhanced steric shielding eﬀect.
Compared to the exponential dependence of the IC50 values on
the inhibitor size because of multivalency, the impact of the
inhibitor size on steric shielding and therefore, the IC50 values,
is relatively weak. Hence, the many reported extremely low IC50
values of ligand decorated globular scaﬀolds,6,10−13,15,20,22 can
now be identiﬁed to be predominantly based on multivalency
eﬀects. A more detailed discussion about the impact of eq 2 on
the prediction of the IC50 values of globular inhibitors is given
in the SI.
The Optimal Inhibitor Size. For applications, the
prediction of the “optimal inhibitor size” is often desirable. In
terms of inhibitor eﬃciency, the optimal inhibitor size might be
best determined by the lowest mass concentration of the
inhibitor. For a general prediction of the optimal size of a
globular inhibitor independently of the scaﬀold material, the
Figure 6. IC50 values determined from (a) BT/SA and (b) dPGS/Sel
assays, respectively. The corresponding dashed lines mark IC50 values
under the assumption that inhibitors bind completely to the binders
with 0.5Pmax[B] for (a) and 0.5Pmin[B] for (b), respectively. The inset
diagram in (b) denotes the ﬁt of the dPGS data to eq 11 with Kd
mono =
94 nM and γ = 0.34 nm−4/3.
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consideration of the volume normalized concentration (which
correlates with the mass normalized concentration) is better
suited as it permits the comparison of inhibitors of diﬀerent
materials. The volume normalization of the inhibition data can
be performed by the multiplication of P (Figure 5) at a speciﬁc
d/D ratio by the factor (d/D)3, respectively (Figure 7a).
The volume normalized values P(d/D)3 which were
calculated by the models for steric shielding, both increase
with higher d/D ratios. Therefore, increasing the size of
inhibitors which bind completely to the binder (Kd
multi ≪
0.5P[B]) is always disadvantageous, as higher mass concen-
trations have to be applied for inhibition. This could be
conﬁrmed by examining the BT/SA assay data (Figure 7a, BT-
NP). For the dPGS/Sel assay, the same eﬀect could be
observed for larger AuNP-dPGS (d/D > 0.3), which was
expectable as the particles were shown to bind completely to
the binders (Figure 3b,c). However, for smaller sized dPGS (d/
D < 0.3), P(d/D)3 decreased with increasing d/D ratios. A
minimum of P(d/D)3 was approached at a d/D ratio of ∼0.3.
At this inhibitor size, the lowest volume and therefore mass of
the inhibitors is required for inhibition. The presence of an
optimum inhibitor diameter can be best described by eq 12,
which is a combination of eq 2 and 11:
= +γ− +d K d P dIC e 0.5 [B]dD d D50 3 dmono [ ( / ) ] 3 3
4/3
(12)
P corresponds to Pmin and Pmax for charged and neutral
inhibitors, respectively. The lower the value of IC50d
3 of an
inhibitor of diameter d, the less volume concentration has to be
applied for 50% inhibition. Independently of the steric shielding
model applied (Pmin or Pmax), the value of the steric shielding
term always increases faster with the inhibitor diameter d than
the cubic increase in volume. Therefore, increasing the size of
inhibitors which bind completely to the inhibitors, i.e., BT-NP
or AuNP-dPGS with a d/D ratio > 0.3 always results in higher
inhibitor volume concentrations at 50% inhibition. However,
the value of the multivalency term always decreases faster than
d3. Hence, for inhibitors which do not bind completely to the
target (Kd
multi ≫ 0.5P[B]), larger inhibitors always result in
lower volumes at the IC50 concentration until a d/D ratio is
approached at which Kd
multi ≈ 0.5P[B]. At this ratio, e.g., 0.3 for
the dPGS/Sel assay (Figure 7a), inhibitors bind completely to
the binder and multivalency eﬀects are negligible.
Equation 12 summarizes all the above-discussed factors,
which determine the required volume concentration of a
globular inhibitor needed for 50% inhibition. For most
applications, however, the investigator knows the binder, i.e.
virus, diameter, and the Kd
mono of the employed ligand. To
highlight the importance of the binder concentration for the
rational design of competitive binding inhibitors, we predicted
the optimal diameter for the inhibition of a hypothetical binder
(D = 100 nm) by a globular binding inhibitor in dependence of
Kd
mono and [B] (Figure 7b).
For the prediction, we employed the same prefactor as
determined for the dPGS/Sel assay (γ = 0.34 nm−4/3) and the
Pmax values appropriate for neutral inhibitors. The plot in Figure
7b is clearly divided into two regimes, namely regime (1) in
which even for smallest inhibitor sizes Kd
multi ≤ 0.5P[B], and
regime (2) in which larger inhibitor diameters are required for
Kd
multi ≈ 0.5P[B], respectively. In the case of regime (1), where
even the smallest inhibitors all bind completely to the binder,
the dependence of the volume concentration at the IC50 is
mainly based on the steric shielding, whereupon larger
inhibitors give higher volume concentrations. Thus, the
multivalent presentation of ligands in regime (1) on globular
inhibitors is disadvantageous. In regime (2), the volume
concentration at 50% inhibition is mainly dictated by
multivalency eﬀects. As the exponential scale of the multi-
valency term is much larger than the cubic increase in volume,
larger inhibitors are always favored up to the optimum d/D
ratio for which Kd
multi ≈ 0.5P[B] holds. Thus, depending on the
concentration of the binder in the application, even for very
strong binding ligand/receptor pairs, e.g., antibodies, the
multivalent presentation of the ligands on a globular scaﬀold
can be advantageous. Nevertheless, as Kd
multi exponentially
increases with larger inhibitor sizes, a complete binding of
inhibitors to the binder is given at an inhibitor diameter of 45
nm (d/D = 0.45) even for a very low binder concentration of
10−20 M and a Kd
mono of 10−6 M. Therefore, the optimum
inhibitor size for the considered conditions is always smaller
than the binder itself.
Just like the ampliﬁcation factor, the binder diameter dictates
the inhibitor/binder contact area and therefore has an
exponential inﬂuence on the optimal inhibitor diameter at
speciﬁc Kd
mono and [B]. Counterintuitively, the optimal inhibitor
sizes for the inhibition of larger binders in comparison to
smaller binders have to be lower at the same concentration, as
Figure 7. (a) Combination of the experimental and theoretical volume
normalized number of inhibitors, P(d/D)3, required to inhibit a binder
from attaching to a planar surface. The data points depicting the
experimental data are colored in red for the dPGS/Sel assay and in
blue for the BT/SA assay, respectively. The continuous lines represent
the predicted values based on the theoretical models for Pmax and Pmin.
(b) Predicted d/D ratios for globular inhibitors which result in the
lowest required volume concentration of inhibitors to reduce the
binding of a hypothetical binder (D = 100 nm) to its target surface by
50% in dependence on Kd
mono and the binder concentration [B]. The
graph can be divided into regimes (1) in which even for the smallest
possible inhibitor size a complete binding to the binder is observed
and (2) in which larger inhibitor diameters are required for a complete
binding of all inhibitors. The black solid line marks Kd
mono = [B].
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increasing the size of the binder also increases the inhibitor/
binder contact area (Figure S11). With lower ampliﬁcation
factors and therefore lower ligand densities, larger inhibitor
diameters are favored as a complete binding of the inhibitors
takes more contact area (Figure S10). The model for steric
shielding (Pmin/Pmax) has only a minor impact on the optimal
inhibitor diameter and is therefore largely irrelevant for
applications (Figure S12).
Interestingly, we have predicted optimal inhibitor diameters
larger than the binder only in those cases where very low ligand
densities or very small binders (<50 nm) prevailed (SI).
Therefore, inhibitor diameters below the size of the binder are
advantageous in most cases. From the experimental data of the
dPGS/Sel and BT/SA inhibition assays, we validated the above
ﬁndings for binder diameters of 46 and 192 nm, respectively
(Figure S13). Since the experimental conditions for the BT/SA
assay were clearly in regime (1), the optimal inhibitor should be
as small as possible (Figure 7a). The experimental conditions
for the dPGS/Sel assay were in regime (2) with an optimal d/D
ratio of 0.3 (Figure 7a).
■ CONCLUSION
The quantiﬁcation of the steric shielding and multivalency
contributions on the IC50 values of diﬀerently sized globular
binding inhibitors provides useful guidelines for the design of
competitive binding inhibitors. The particle and volume
normalized IC50 value of an inhibitor at very low binder
concentrations [B] predominantly depends on its multivalent
dissociation constant Kd
multi. The Kd
multi and thus the IC50 values
show an exponential dependence on the inhibitor/binder
contact area. Hence, the IC50 values of larger sized inhibitors
are often observed to be several orders of magnitude lower
compared to the monovalent ligand.4,5,10−13,20 As the increase
in contact area with inhibitor size levels oﬀ for binder-sized
inhibitors, this eﬀect is more pronounced at lower inhibitor/
binder size ratios. Compared to the multivalency eﬀects, the
contribution of steric shielding to the IC50 values of inhibitors is
only minor, and its impact is only noticeable if Kd
multi ≪
0.5P[B], meaning if all inhibitors are bound to the binder. In
this case, an increase in inhibitor size is unfavorable, as the
volume and therefore mass of the inhibitor increases faster with
inhibitor size than the steric shielding contribution. Most
importantly, it is necessary to emphasize the dependence of the
predominant eﬀect (steric shielding or multivalency, respec-
tively) on the binder concentration. Because of the exponential
dependence of Kd
multi on the contact area, especially larger sized
inhibitors often have multivalent dissociation constants far
below the experimental binder, i.e., virus, concentration so that
only steric shielding eﬀects can be observed. The concentration
of viruses in the body ﬂuids of infected individuals is often
several order of magnitudes lower, in which case lower Kd
multi
(meaning larger inhibitors and/or higher ligand functionaliza-
tion) would be of major advantage. Because of the quantitative
relationship between inhibitor volume, multivalency eﬀects, and
steric shielding, the optimal size of a globular inhibitor for the
lowest volume normalized IC50 value provides just enough
contact area for inhibitors to bind completely to the binder at
the given binder concentration. Our predictions show that
optimal inhibitor diameters are in most cases smaller than the
binder itself.
Besides globular inhibitors, sheet-like inhibitors should have
a very high potential. They provide very large contact areas at
low volumes, which is a prerequisite for eﬃcient volume
normalized inhibition. In future projects, we will adopt our
model for competitive binding inhibition to other geometrical
structures to facilitate the rational design of competitive binding
inhibitors for the eﬃcient treatment of viral diseases.
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